Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson’s disease: a randomised, single-blinded, phase 1 trial

The Lancet Neurology

Fecha de publicación: July 2020


Autores: Dieter Volc, MD., Prof Werner Poewe, MD., Alexandra Kutzelnigg, MD., Petra Lührs, PhD., Caroline Thun-Hohenstein, MD., Achim Schneeberger, MD., et al.

Background: Robust evidence supports the role of α-synuclein pathology as a driver of neuronal dysfunction in Parkinson’s disease. PD01A is a specific active immunotherapy with a short peptide formulation targeted against oligomeric α-synuclein. This phase 1 study assessed the safety and tolerability of the PD01A immunotherapeutic in patients with Parkinson’s disease.

Seguir leyendo

Enviar comentario